Day 3 Program

Poster Session 4

Day 3: December 10, 2026

5:00 PM–6:30 PM CST

Exhibit Hall

Session Details

P4-1-01

Hierarchical Clustering of Daily Symptom Reports Identifies Symptom Groupings in Breast Cancer Survivors

Lerick Sequeira, Florida International University, Miami, FL

P4-1-02

Mammographic Breast Density Trajectories After Breast Cancer: Implications for Survivorship Risk Stratification

Amber N Hurson, National Cancer Institute, Rockville, MD

P4-1-03

Bringing Psychological Care to the Point of Diagnosis: Patient Satisfaction and Physician Burnout Following Implementation of an Embedded Psychology Program

Carrie A Bronars, Mayo Clinic, Rochester, MN

P4-1-04

Intimate Partner Violence and Overall Survival among Older Women with Breast Cancer

Inimfon Jackson, The University of Texas MD Anderson Cancer Center, Houston, TX

P4-1-05

Improving Quality of Life in Patients Surviving Breast Cancer through a Cardiometabolic Screening Program

Akhila Rao, Johns Hopkins University, Baltimore, MD

P4-1-06

Fertility Preservation, Post-Treatment Reproductive and Oncologic Outcomes in Women with Breast Cancer. Results from EMBARCAM Study (GEICAM/2017-07)

Begoña Bermejo, Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain

P4-1-08

Delayed Endocrine Immune-Related Adverse Events after Pembrolizumab in Young and Older Adults with Early-Stage Triple Negative Breast Cancer

Raymart Macasaet, TidalHealth Peninsula Regional Hospital, Salisbury, MD

P4-1-09

Physical function data collection to assess chemotherapy tolerability in patients with breast cancer

Kathryn J Ruddy, Mayo Clinic, Rochester, MN

P4-1-10

Health-related quality of life after 12-month of structured lifestyle intervention program in women treated for early breast cancer

Livia S. A. Augustin, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy

P4-1-11

Menopausal Symptom Trajectories and Medical Recommendations in Breast Cancer Survivorship Care: Identifying Opportunities for Multidisciplinary Support

Haydee Cristina Verduzco-Aguirre, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Mexico

P4-1-12P

Changing Trends in Cardiovascular Hospitalizations Among Patients with Breast Cancer in the United States

Divya Solipuram, Medical University of South Carolina, Charleston, SC

P4-1-14

Well-being after breast cancer surgery (WB ABCs, NCT04225585): characteristics of patients with persistent postsurgical pain in a multi-institutional randomized clinical treatment trial

Gregory Paul Stimac, University of Pittsburgh School of Medicine, Pittsburgh, PA

P4-1-15

A Community Pharmacist-Led Program to Support Women Prescribed Adjuvant Endocrine Therapy After Breast Cancer: A Pilot Cluster-Randomized Controlled Trial

Sarah Jeanveaux, Université Laval, Quebec city, QC, Canada

P4-1-16

Breast cancer history impacts menopause symptom phenotypes

Jaime Castillo Silva, Mayo Clinic, Jacksonville, FL

P4-1-17

Five-year sleep quality trajectories after breast cancer diagnosis: a prospective study from the Alberta Moving Beyond Breast Cancer (AMBER) cohort

Lin Yang, Cancer Care Alberta, CALGARY, AB, Canada

P4-1-19

Sexual and Reproductive Outcomes After Neoadjuvant Chemotherapy Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer: A Real-World Analysis from the Neo-Real/GBECAM-0123 Study

Renata Colombo Bonadio, Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil

P4-1-20

The PREFACE Study: Proof-of-Concept Implementation of a Diagnosis-Time Algorithm-Triggered Survivorship Pathway Translating Risk Prediction into Personalized Risk Communication and Management of Modifiable Risk Factors

Ines Vaz-Luis, Gustave Roussy, Villejuif, France

P4-1-21

Evaluation of 10mg Hyaluronic Acid Suppositories in Breast Cancer Patients Experiencing Treatment Induced Genitourinary Symptoms of Menopause

Shari Goldfarb, MSKCC, New York City, NY

P4-1-22

Routine Guideline-Discordant Surveillance Imaging and the Trajectory of Fear of Cancer Recurrence Among Adjuvant Chemotherapy-Treated Early Breast Cancer Survivors

Filippos Koinis, University Hospital of Larissa, Larissa, Greece

P4-1-23

Improving Access, Reducing Barriers, and Enhancing Patient Experience through Susan G. Komen’s Breast Care Helpline

Krista Park Berry, Susan G Komen, Dallas, TX

P4-1-26

Work Productivity and Daily Activity Impairment in the Breast Cancer Weight Loss (BWEL) Trial (Alliance A011401)

Ruixuan Wang, Dana-Farber Cancer Institute, Boston, MA

P4-1-27

Prospectively collected patient experience (Breast -Q) of skin toxicity and breast/chest wall well-being from regional nodal irradiation post lumpectomy or mastectomy<sup></sup>

Sunitha Susan Varghese, The University of Kansas Medical Center, Kansas City, KS

P4-1-28

Cannabis Use and Breast Cancer Risk: Implications for Prevention Counseling and Survivorship Care

Ann Pittier, Tacoma Valley Radiation Oncology, Tacoma, WA

P4-1-29

Longitudinal Changes in Advance Care Planning Engagement, Patient Preferences, and Patient-Family Concordance in Japanese Breast Cancer Patients and Their Families: A Follow-up Study (Follow-up to SABCS 2025 #2025-A-2256: “Discordance in End-of-Life Decision-Making”)

Kazunoshin Tachibana, Fukushima Medical University School of Medicine, Fukushima, Japan

P4-1-30

Vaginal Estrogen and Alternatives to Menopause Hormone Therapy use in Breast Cancer Survivors

Margo Nelis, Cleveland Clinic Foundation, Cleveland, OH

P4-2-02

The costs of late-stage breast cancer diagnosis: Findings from the Cancer Experience Registry

Erica E Fortune, Cancer Support Community, Washington DC, DC

P4-2-03

Launch of a new French Cancer Survivorship Cohort – Constances SCALA: the baseline profile of breast cancer survivors

Valerie McCormack, International Agency for Research on Cancer, Lyon, France

P4-2-04

Temporal trends in Contralateral Breast Cancer Risk by Estrogen Receptor Status Among Breast Cancer Survivors: A Population-Based SEER 12 Study, 1992-2023

Michelle O Sodipo, National Cancer Institute, National Institutes of Health, Bethesda, MD

P4-2-05

Post-diagnosis depression, mortality, and psychosocial morbidity in endocrine-treated hr+/her2− breast cancer: a propensity-matched real-world analysis

Anna Homeniuk, UPMC Central PA, Harrisburg, PA

P4-2-06

Efficacy and safety of non-hormonal therapy for vasomotor symptoms in women with breast cancer on adjuvant endocrine therapy: A systematic literature review

Ann H Partridge, Dana-Farber Cancer Institute, Boston, MA

P4-2-07

Short-term and long-term symptoms after DCIS treatment

Ahauve M. Orusa, Mayo Clinic, Rochester, MN

P4-2-08

Fear of Cancer Recurrence and Health-Related Quality of Life in Early-Stage Breast Cancer Survivors: A Multicenter Uruguayan Study

Natalia Camejo, Hospital de Clinicas, Montevideo, Uruguay

P4-2-09

Patient Informed Development of Culturally Responsive Digital Peer Support for Black and Hispanic Women with Metastatic Breast Cancer

Taylarr Lopez, National Minority Quality Forum, Washington, DC

P4-2-10

The Impact of Adjuvant CDK 4/6 Inhibitor Therapy on Quality of Life in Patients with Early Breast Cancer: Real-world evidence

Charlotte Verbeke, KU Leuven, Leuven, Belgium

P4-2-11

Exploring Treatment Patterns and Outcomes in Men with Breast Cancer

Kikelola Oyeleye, Vanderbilt University Medical Center, Nashville, TN

P4-2-12

Longitudinal Associations of Individual and Group Psychological Support With Distress and Quality of Life in Women With Breast Cancer

Marina Campione, ARNAS Civico Di Cristina Benfratelli Hospital, Palermo, Italy

P4-2-13

Project 528 U.S. Findings: Patient-centered data on the experiences and Unmet needs of young adults with breast cancer (2022-2024).

Mary Ajango, Young Survival Coalition, New York, NY

P4-2-16

Cardiac monitoring during treatment with anthracycline-based chemotherapy with or without trastuzumab and long-term risk of cardiomyopathy and heart failure among early-stage breast cancer patients

Cody Ramin, Cedars-Sinai Medical Center, Los Angeles, CA

P4-2-17

Characterizing vasomotor symptom burden in women with breast cancer on adjuvant endocrine therapy: a systematic review and meta-analysis

Laurentia Wahyudi, Bayer Consumer Care AG, Basel, Switzerland

P4-2-18

Implementing Patient-Reported Outcome Measures in LMIC Breast Surgery: Advancing towards Value-Based Care using FACT-B.

Shifan Abbasi, Aga Khan Univeristy, Karachi, Pakistan

P4-2-19

Hearing/vestibular problems and cognitive function in a multiethnic follow-up cohort of breast cancer survivors

Jincong Q. Freeman, UChicago Medicine Comprehensive Cancer Center, Chicago, IL

P4-2-20

Salvage mastectomy does not compromise patient-reported health-related quality of life outcomes following prior breast-conserving surgery

Claire Liu, University of British Columbia, Vancouver, BC, Canada

P4-2-21

Baseline Nanomechanical Tissue Phenotyping Predicts Patient Reported Outcomes Following Implant Based Breast Reconstruction: Results from the Prospective EMPOWER Study

Papa Diogop Ndiaye, ARTIDIS AG, Basel, Switzerland

P4-2-22

Community oncologists’ perceptions of the PREFER trial and fertility preservation practices in early breast cancer

Brooke Leon, Cardinal Health, Dublin, OH

P4-2-23

Internalized Medical Authority and Treatment Engagement Among People Living with Metastatic Breast Cancer: Findings From a Patient-Led Survey

Mya Roberson, University of North Carolina at Chapel Hill, Chapel Hill, NC

P4-2-24

Implementation of a Multidisciplinary Webinar Series to Address Unmet Survivorship Needs in Young Patients With Breast Cancer

Esther Chong, Oregon Health and Sciences University, Portland, OR

P4-2-25

Implementing Proactive Community-Based Supportive Care Referral Pathways in Breast Cancer Care: A Multi-Site Implementation Study

Danna Remen, Ellie Fund, Needham, MA

P4-2-26

Early Accelerometer-Derived Upper-Limb Activity Independently Predicts 12-Month Disability After Breast Cancer Surgery

Masahiro Manfuku, Breast Care Sensyu Clinic, Kishiwada, Japan

P4-2-27

Racial Disparities in Stage at Diagnosis, Treatment Receipt, and Breast Cancer-Specific Survival by Subtype Among Women under 55: A Population-Based SEER Analysis

Omofolarin Debellotte, University of Wisconsin School of Medicine and Public Health, Madison, WI

P4-2-28

Patient-reported outcomes measure for assessing symptom burden in patients living with breast cancer, MDASI-Br-Chemo and MDASI-Br-Surv

Meagan Whisenant, Cizik School of Nursing, UTHealth Houston, Houston, TX

P4-2-29

Moving Forward Together for Recovery: A Collaborative Guide for Researchers and Cancer Care Organizations

Karen E Wickersham, University of South Carolina, Columbia, SC

P4-2-30

Implementation and Evaluation of a Community-Based Shared Care Pathway for Breast Cancer Survivors in a Rural Medical Region in Japan

Michiko Harao, Jichi Medical University, Shimotsuke, Japan

P4-3-01

Advancing Evidence on the Care for HER Program: The Impact of Patient Navigation and Integrative Services in the Black Breast Cancer Community

Sue Weldon, Unite for HER, Malvern, PA

P4-3-02

Bmi and physical quality-of-life burden during endocrine therapy in women veterans with hormone receptor-positive breast cancer: a prospective cohort study

Giorgi Sabakhtarishvili, George Washington University, Washington, DC

P4-3-03

Patient-reported effectiveness and tolerability of fezolinetant for vasomotor symptoms in patients with breast cancer on endocrine therapy: a survey across two institutions

Stephanie Adel Haddad, UT Health San Antonio/Mays Cancer Center, San Antonio, TX

P4-3-04

Factors Affecting the Decision to Opt for Risk Reducing Surgery in high-risk Jordanian women with pathogenic germline mutations

Mahmoud Al-Masri, King Hussein Cancer Center, Amman, Jordan

P4-3-05

Uptake of Fertility Preservation Among BRCA1/2 Mutation Carriers Unaffected by Breast or Ovarian Cancer

Sara Chemel, New York University Grossman School of Medicine, New York, NY

P4-3-06

From Recommendations to Results: Improved AICR/WCRF Adherence and Durable Skeletal Muscle at 6 Months in Early-Stage Breast Cancer

Sami Mansfield, Cancer Wellness for Life, Green Cove Springs, FL

P4-3-07

Sexual distress and functional sexual impairment represent distinct dimensions of sexual health in women with newly diagnosed breast cancer

Anne Dominique Nascimento Lima, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

P4-3-08

Glp-1 receptor agonists and cardiovascular outcomes in women with type 2 diabetes receiving cdk4/6 inhibitors for hr+/her2- metastatic breast cancer: a propensity-matched trinetx analysis

Mandeep Singh, University of Rochester Medical Center, Rochester, NY

P4-3-09

Obstetric and Oncologic Outcomes of Patients with Pregnancy After Breast Cancer: A Real-World Cohort

Rubem Moreira, Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil

P4-3-10

Ht Helper: evaluating a bilingual mobile health and patient navigation intervention to support hormone therapy adherence in Latina breast cancer patients

Patricia Chalela, UT Health San Antonio, San Antonio, TX

P4-3-11

Managing vasomotor symptoms in breast cancer survivors: systematic review and meta-analysis of non-hormonal interventions

Claudia Calderaio, IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy

P4-3-12

Supporting survivorship, advancing patient-centered research: Susan G. Komen’s research advocacy program as a model for readiness-based engagement and impact

Liz R Graves, Susan G. Komen, Dallas, TX

P4-3-13

Patient Centered Dosing Initiative: Patient-reported impact of metastatic breast cancer treatment toxicity on daily living and management strategies

Elizabeth L Papautsky, University of Illinois Chicago, Chicago, IL

P4-3-14

Risk-adapted follow-up strategies in early breast cancer: a 2026 consensus project

Luca Arecco, Institut Jules Bordet, Bruxelles, Belgium

P4-3-15

An integrated positive psychology and health coaching model for quality of life in breast cancer survivors in a middle-income country: results from two complementary studies.

Gisele S Gengo, Instituto OncoSuperação, São Paulo, Brazil

P4-3-16

Characterization of antibody-drug conjugate-induced alopecia and its effects on quality of life in female patients with breast cancer

Melina Seng, The Ohio State University, Columbus, OH

P4-3-17

Self-report of symptoms, supportive care utilization, and quality of life by subtype among patient living with stage IV breast cancer for longer than a year

Ashley P Davenport, The Ohio State University College of Medicine, Columbus, OH

P4-3-18

Psychological Resilience and Quality-of-Life Outcomes During Endocrine Therapy in Women Veterans With Hormonal Positive HER2-Negative Breast Cancer: A Prospective Cohort Study

Sarah Y. Liu, Institute of Clinical Research, DC VA Medical Center, Washington, DC

P4-3-19

Disparities in Fertility Preservation Counseling and Access Among Young Women With Breast Cancer in Brazil: A Comparison Between Public and Private Healthcare

Renata Cerqueira, Hospital Mater Dei, Belo Horizonte, Brazil

P4-3-20

Impact of diet on menopausal symptoms in women experiencing natural menopause and induced by breast cancer treatments

Lucia Higueras Santamaria, MD Anderson Cancer Center Madrid-Hospiten, Madrid, Spain

P4-3-21

Association of Patient-Reported Psychosocial Distress with Transcriptional Signatures and Spatial Immune Architecture in Breast Cancer

Shipra Gandhi, Winship Cancer Institute of Emory University, Atlanta, GA

P4-3-22

Impact of Breast Reconstruction on Quality of Life and Body Image in Mexican Breast Cancer Patients: Real-World Evidence

Saul Campos Gomez, Centro Oncológico Estatal ISSEMyM, Toluca de Lerdo, Mexico

P4-3-23

Patient and Healthcare Provider Perspectives on Subcutaneous Pertuzumab/Trastuzumab: A Multidisciplinary Survey from Real-World Clinical Practice

Emi Kanaya, University of Toyama, Toyama, Japan

P4-3-24

Age Stratification Reveals Hidden Survival Trends in Advanced Breast Cancer: Insurance, Race/Ethnicity, and Histology Interact with Age at Diagnosis

Pranav K Kandikuppa, Medical College of Georgia, Augusta, GA

P4-3-25

Clinical characteristics and menopausal symptom burden in patients with breast cancer evaluated in a women's cancer wellness clinic

Devin K. Johnson, UNC Hospitals, Chapel Hill, NC

P4-3-26

Understanding Breast Cancer Survivorship Through Social Media: A Cross-Sectional Analysis of Content, Engagement, and Misinformation on TikTok

Eleni M. Drivas, Westchester Medical Center, Valhalla, NY

P4-3-27

Early cachexia and iliopsoas muscle volume trajectory predict survival in de novo metastatic breast cancer

Katherine Lei, University of Texas Southwestern Medical Center, Dallas, TX

P4-3-28

Higher Symptom Burden Is Associated with Increased Comorbidity in Patients with Metastatic Breast Cancer

Abbey J Kaler, The University of Texas MD Anderson Cancer Center, Houston, TX

P4-3-29

Implementation and impact of a national shared-care breast cancer survivorship program between tertiary oncology and primary care: A quality improvement project from Qatar.

Ahlam Mohammad, National Centre for Cancer Care and Research Doha, Qatar, doha, Qatar

P4-3-30

Developing and Evaluating an OncoChat Tool Tailored to the Information Needs of Women Newly Diagnosed with Breast Cancer

Pei-Ju Lien, Taipei Veterans General Hospital, Taipei, Taiwan, Taiwan

P4-4-02

Twenty-five years of progress, persistent gaps, and emerging priorities: lesson's from canada's largest community of younger women with breast cancer

Mj DeCoteau, Rethink Breast Cancer, Toronto, ON, Canada

P4-4-03

Changes in Sexual Health Following Curative Treatment in Young Women with Breast Cancer

Renata Cerqueira, Hospital Mater Dei, Belo Horizonte, Brazil

P4-4-04

Chest CT detects acute lung injury in 16.1% of patients during breast-cancer chemotherapy: association with cumulative cyclophosphamide and older age

Yang Yang, Peking University Cancer Hospital, beijing, China

P4-4-05

Bridging survivor experience and epidemiologic research: The NCI-Kaiser Permanente Breast Cancer Survivors Cohort community partners initiative

Jacqueline B Vo, Emory University, Atlanta, GA

P4-4-06

Mpynk: qualitative needs assessment of young women living with metastatic breast cancer

Jordan Rivera, Sinai Health System, Toronto, ON, Canada

P4-4-07

Integrating psychiatric pharmacogenomics in breast cancer care: provider perspectives and clinical utilization in patients with comorbid emotional distress

Kadie Harry, BJC Health Saint Luke's Cancer Institute, Kansas City, MO

P4-4-08

Early volumetric behavior following breast-conserving surgery using liquid-type acellular dermal matrix: a retrospective pilot study based on radiotherapy planning CT

Ji Young You, Korea University, Seoul, Korea, Republic of

P4-4-09

Communication Experiences and Preferences around Breast Cancer Treatment Side Effects among ShareForCures® Research Registry Participants

Sofia Huster, Susan G. Komen, Dallas, TX

P4-4-10

Impact of Positive Psychology and Behavioral Profiling on Patient Agency and shared decision-making: The superar program as a model for breast sancer survivorship

Gisele Sales Gengo, Instituto OncoSuperação, São Paulo, Brazil

P4-4-11

Exploring oncology-primary care transitions and utilization among long-term breast cancer survivors in rural and medically underserved communities

Vanessa Torres, Cedars-Sinai Medical Center, Los Angeles, CA

P4-4-12

Impact of involvement: bringing Patient Research Advocate perspectives to collaborative pre-clinical research within Cancer Grand Challenges Team MATCHMAKERS

Michele Rakoff, Breast Cancer Care and Research Fund, Los Angeles, CA

P4-4-13

Grupo Despertar: A Peer-Led, Survivor-Run Breast Cancer Support Program for Vulnerable Women in Northeastern Brazil

Karla Emerenciano, Liga Norte Riograndense Contra o Câncer, Natal, Brazil

P4-4-14

A collaborative, peer-led model for breast cancer survivorship: integrating psychosocial rehabilitation and regional outreach in Georgia and the Caucasus

Lolita Abramova, Phoenix and Cancer Society Hope, Tbilisi, Georgia

P4-4-15

Cognitive effects of endocrine therapy in breast cancer: a systematic review

Elif Koca, Istanbul University-Cerrahpasa, Cerrahpasa Faculty Of Medicine, Istanbul, Turkey

P4-4-16

The relationship between psychological hardness and purpose in life among breast cancer patients

Khatuna Tchintcharashvili, Caucasus Cancer Society Hope, Tbilisi, Georgia

P4-4-17

Rapid Drug Desensitization After Infusion Reactions in Breast Cancer: a Single-Center Experience (2014-2025)

Irene Palmieri, Ospedale Infermi, Rimini, Italy

P4-4-18

Financial Toxicity and Persistence of Self-Reported Nonadherence Among Hispanic/Latina Breast Cancer Survivors: A 12-Month Longitudinal Analysis

Sammuel Cepeda, UT Health San Antonio, San Antonio, TX

P4-4-19

Factors that influence patient-oncologist communication and engagement among Black women with advanced-stage breast cancer receiving care in the Mid-South region of the United States

Janeane N Anderson, University of Tennessee Health Science Center, Memphis, TN

P4-4-20

The lived experience of women with locally advanced or metastatic triple‑negative breast cancer: patient‑reported symptoms, impacts, and trial expectations

Tiffany Traina, Memorial Sloan Kettering Cancer Center, New York, NY

P4-5-01

Inflammatory activation coupled with inhibitory immune signalling characterises ethnicity-associated immune remodelling in ER+/HER2− breast cancer

Sophie Stewart, King's College London, London, United Kingdom

P4-5-03

Racial Disparities in Overall Survival Among Patients with Early-Stage Hormone Receptor Positive HER2 Negative (HR+/HER2−) Invasive Lobular Carcinoma Receiving Adjuvant Chemotherapy

Arya Mariam Roy, The Ohio State University, Columbus, OH

P4-5-04

Real-world outcomes and efficacy of sacituzumab govitecan in black and white patients with metastatic breast cancer

Almeera Lateef, Emory University, Atlanta, GA

P4-5-05

Neighborhood disadvantage and stage of breast cancer diagnosis in a diverse urban safety-net population

Karina P Verma, Boston Medical Center / Boston University Chobanian & Avedisian School of Medicine, Boston, MA

P4-5-06

Sex Based Differences in Hospitalizations Characteristics, Comorbidity Burden and Inpatient Outcomes Among Breast Cancer Admissions: A National Inpatient Comparison

Lydia Francis, UTHSCSA, San Antonio, TX

P4-5-07

Violence among women with metastatic breast cancer in Mexico

Yanin Chavarri-Guerra, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

P4-5-08

The Distance Paradox: Geographic Access to Care and Treatment Receipt in Breast Cancer

Abigail Kaminsky, Albany Medical College, Albany, NY

P4-5-09

Premenopausal status as an access barrier to aromatase inhibitor-based treatment for HR+/HER2- advanced breast cancer in LMICs

Marine Durand, The Max Foundation, Seattle, WA

P4-5-10

The Reporting Paradox: Race, Ethnicity, and Underrepresentation in Phase III Metastatic Breast Cancer Trials (2015-2025)

Erika Bushatsky Andrade de Alencar, Jewish General Hospital, McGill University, Montreal, QC, Canada

P4-5-11

Treatment and Survival Disparities by Immunohistochemical Subtypes of Advanced Breast Cancer in Latin America: A LATINA Breast Study Subanalysis

Gustavo Werutsky, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil

P4-5-12

Treatments and outcomes in metastatic triple-negative breast cancer by race: a US secondary data retrospective study

Jade Jones, Winship Cancer Institute of Emory University, Atlanta, GA

P4-5-13

A late and widening survival gap by health insurance despite guaranteed treatment in HR+HER2− breast cancer: a multicentre cohort study in Chile

Benjamin Walbaum, Pontificia Universidad Catolica de Chile, Santiago, Chile

P4-5-14

Retrospective study of the association between race/ethnicity, neutropenia, CDK 4/6 inhibitor dosing, and outcomes in metastatic hormone receptor-positive, HER2-negative breast cancer

Meghan Elizabeth Acheson, Washington University in St. Louis, Saint Louis, MO

P4-5-15

Breast Cancer Hub's Door-to-Door Breast Cancer Screening and Treatment Model Addressing Access Disparities in Rural West Bengal, India (2022-2026): A Sustainable Framework for Developing Countries

Lopamudra Das Roy, Breast Cancer Hub, Concord, NC

P4-5-16

Global inequities in breast cancer clinical trials: country-level alignment between trial activity and disease burden, 2020-2025

Erika Bushatsky Andrade de Alencar, Jewish General Hospital, McGill University, Montreal, QC, Canada

P4-5-17

Age-related differences in pathological complete response following neoadjuvant chemotherapy with or without immunotherapy in stage ii-iii node-positive triple-negative breast cancer: a national cancer database analysis

Yolcar Chamorro, Baptist Health Herbert Wertheim Cancer Institute, Miami, FL

P4-5-18

A drug-responsive Hedgehog/Vitamin D Receptor boundary niche in normal breast tissue is enriched in non-Hispanic Black women and linked to basal/triple negative breast cancer biology

Nicole Cruz-Reyes, Mayo Clinic FL, Jacksonville, FL

P4-5-19

Variation in TILs and PD-L1 expression related to African ancestry

Lisa Newman, Weill Cornell Medicine, New York, NY

P4-5-20

Area-level social risk exposure and personalized cancer risk assessment among invasive breast cancer patients

Lendy Chu, University of Chicago, Chicago, IL

P4-5-21

Patient Navigation and Healthcare Access Among Breast Cancer Patients Undergoing Radiotherapy

Afua Ofori-Darko, Case Western Reserve University, Cleveland, OH

P4-5-22

Association between Neighborhood-Level Socioeconomic Deprivation and Use of Integrative Therapies in Patients with Breast Cancer

Ashley Hardeman, University of Chicago, Chicago, IL

P4-5-23

The Influence of Race and Socioeconomic Status on Inpatient Palliative Care Integration During Terminal Admissions for Metastatic Breast Cancer

Jennifer Hsu, Brown University, Providence, RI

P4-5-24

Her2 gene amplicon expression and real world survival in hispanic vs non-hispanic white patients with her2+ breast cancer

Robert Hsu, University of Southern California, Los Angeles, CA

P4-5-25

Impact of Pre-existing HIV on Breast Cancer Outcomes: A Propensity-Matched Real-World Analysis

Anna Homeniuk, UPMC Central PA, Harrisburg, PA

P4-5-26

Treatments and outcomes in HR+ HER2- metastatic breast cancer by race: a US secondary data retrospective study

Manali Bhave, Winship Cancer Institute of Emory University, Atlanta, GA

P4-5-27

Social Vulnerability, Race/Skin Color, and Geographic Disparities in Breast Cancer Stage at Diagnosis and Mortality in Brazil: A Population-Based Study of 1,034,529 Patients (CARE-LACOG/CURA 1424)

MAX S. MANO, Latin American Cooperative Oncology Group (LACOG) and Einstein Hospital Israelita, Sao Paulo, Brazil

P4-5-28

Transportation barriers among breast cancer patients with limited English proficiency in the COVID-19 era

Thomas Amburn, New York University Grossman School of Medicine, New York, NY

P4-5-29

Structural and socioeconomic factors may drive disparities in lobular breast cancer diagnosis

Matthew J. Sikora, University of Colorado Anschutz, Aurora, CO

P4-5-30

Racial disparities in the burden of young-onset breast cancer: a SEER-based study

Gabrielle Williams, Queen's University, Kingston, ON, Canada

P4-6-01

Mapping Global Evidence Gaps in Triple Negative Breast Cancer Stage-at-Diagnosis Research: A Scoping Review

Amalia Abraham, Florida International University Herbert Wertheim College of Medicine, Miami, FL

P4-6-02

Sex-based differences in complication burden among adults hospitalized with breast cancer, 2016-2023

Audrey Efendi, Comprehensive Cancer Centers of Nevada, Central Valley, Las Vegas, NV

P4-6-03

Disparities in Breast Cancer Screening: Insights From an Adult Female Outpatient Population in the Northeastern United States.

Samantha El Warrak, University of Miami/Sylvester Cancer Center, Miami, FL

P4-6-04

Disparities in breast cancer clinical trial enrollment: a quantitative and qualitative analysis of patient perspectives.

Constance Fiocco, NYU Langone Health – Perlmutter Cancer Center, New York, NY

P4-6-05

Breast Cancer Trends in Females across 204 WHO regions: 30 year comparative analysis from GBD 2021 study

Niyati Shambhubhai Avaiya, SUNY Upstate Medical University, Syracuse, NY

P4-6-06

Geographic Disparities in Advanced-Stage Presentation of Triple-Negative Breast Cancer: Analysis of 36,690 Patients from the National Cancer Database

Berkay Demirors, University of Pittsburgh, Pittsburgh, PA

P4-6-07

Factors associated with advance directive documentation in patients with metastatic breast cancer

Lekha Yadukumar, University of Iowa Hospitals and Clinics, Iowa City, IA

P4-6-08

Narrowing racial disparities in adjuvant systemic treatment in women with early breast cancer

Stephanie S Massimilian, Memorial Healthcare System, Pembroke Pines, FL

P4-6-09

Clinical impact and sociodemographic disparities following cessation of breast cancer screening program at age 75: A population-based cohort study

Yael Berner-Wygoda, Hadassah University Hospital, Jerusalem, Israel

P4-6-10

Lifestyle Exposure Profiles Among Women of Quilombola Descent With Breast Cancer: An Unsupervised Cluster Analysis

Danielle Calheiros Campelo Maia, PRONUTRIR, FORTALEZA, Brazil

P4-6-11

Urban Legend? Examining the Rural vs Urban Relationship in Breast Cancer Histological Prevalence Trends

Majd Aboul Hosn, Dartmouth Hitchcock, Lebanon, NH

P4-6-12

Cardiovascular disease mortality among breast cancer survivors by race and estrogen receptor status in the U.S., 2006-2021

Xinyi Feng, Emory University, Atlanta, GA

P4-6-14

Beyond Erythema: Race-Based Differences in Breast Discoloration Among Patients with Inflammatory Breast Cancer (IBC)

Filipa Lynce, Dana-Farber Cancer Institute, Boston, MA

P4-6-15

Breast Cancer Screening Practices and Perceived Barriers to Early Detection Among Syrian Women: National Cross-Sectional Study

Hira Munir, Advocate Health Care, Chicago, IL

P4-6-16

Disparities in Treatment-Related Inpatient Cardiotoxic Complications Among Patients Receiving Systemic Therapy for Breast Cancer: A 2023 National Inpatient Sample Analysis

Namitha Thotli, UT San Antonio, San Antonio, TX

P4-6-17

Breast cancer in young Chilean women: Treatment patterns and survival in a resource limited setting.

Andrea Sepulveda, Hospital Santiago Oriente, santiago, Chile

P4-6-18

Treatment Outcomes and Biomarker Testing Disparities Across Lines of Therapy in a Predominantly Hispanic Cohort with HR+/HER2- Metastatic Breast Cancer at an Urban Safety-Net Hospital

Anastasia Martynova, University of Southern California, Los Angeles, CA

P4-6-19

Temporal Trends in Gender-Related Language in Breast Cancer Clinical Trial Eligibility Criteria (1977-2025)

Vanessa Ayafor, Saint Mary's Hospital, Waterbury, CT

P4-6-20

Routine Social Determinants of Health Screening Identifies Patient and Neighborhood Level Disparities in a Community Breast Oncology Practice

Akshay Pandya, St. John's School, Houston, TX

P4-6-22

Racial Disparities in Aromatase Inhibitor-Associated Pain Interference Among Chinese American and Non-Hispanic White Breast Cancer Survivors

Keri Cronin, Mount Sinai West, New Yok, NY

P4-6-25

Opposing Survival Trends by Stage: Black-White Breast Cancer Disparities Among Women Younger Than 50 Years

Tiffany Calero, Los Robles Regional Medical Center, Thousand Oaks, CA

P4-6-26

Tumour Biology and Healthcare System as Determinants of Stage at Breast Cancer Diagnosis: An International Multicentre Cohort Study Across Central America and Spain

Denis Ulises Landaverde, Mexico Hospital, San Jose, Costa Rica

P4-6-27

Racial Disparities and Clinical Burden of Thromboembolic Complications Among Breast Cancer Hospitalizations: A National Inpatient Sample Analysis

Tijin A Mathew, LSUHS, Shreveport, LA

P4-6-28

Germline Mutation Spectrum and Variants of Uncertain Significance Burden in aHispanic/LatinoBreast Cancer Cohort at an NCI-Designated Cancer Center.

Marcela Mazo Canola, UT Health San Antonio, San Antonio, TX

P4-6-29

Sociodemographic Inequalities in Breast Cancer Mortality among Brazilian Women between 1996-2024: A Nationwide Ecological Study

Angela Theresa Zuffo Yabrude, Universidade Regional de Blumenau, Blumenau, Brazil

P4-6-30

Design of an Implementation Blueprint to Reduce Breast Cancer Disparities Using Health-Equity-Informed Implementation Science

Anand K Narayan, University of Wisconsin Carbone Cancer Center, Madison, WI

P4-8-01

Beyond the Monolith: Item-Level and Ethnicity-Stratified Analyses Reveal Distinct Determinants of Breast Cancer Screening Among South Asian and Middle Eastern Muslim Women

Sulastri Kamis, Columbia University, New York, NY

P4-8-03

Disparities in Dollars and Demographics: Examining Income and Ethnic Divide in Breast Cancer Histological Trends

Majd Aboul Hosn, Dartmouth Hitchcock, Lebanon, NH

P4-8-05

Beyond Treatment Utilization: Area Deprivation Index and Survival Outcomes in Metastatic Breast Cancer

Regina Shrestha, Dartmouth Hitchcock Medical Center, Lebanon, NH

P4-8-06

Rethink Breast Cancer: Addressing Disparities in Cancer Care among patients with Metastatic Breast Cancer in BC, Canada

Anshini Shah, BC Cancer, Vancouver, BC, Canada

P4-8-08

Neighborhood socioeconomic status and outcomes of patients with metastatic breast cancer with uniform healthcare access

Ayelet Shai, RAMBAM Health care Campus, Haifa, Israel

P4-8-09

Racial and Ethnic Differences in Age at Diagnosis of Classic Lobular Carcinoma In Situ: A SEER Analysis, 2000-2022

Jasneet Gill, NORTH KNOXVILLE MEDICAL CENTER, KNOXVILLE, TN

P4-8-10

Racial Disparities in Breast Cancer-Specific Survival Among American Indian/Alaska Native Women Across Breast Cancer Subtypes: A SEER Analysis

Sreeja Ponnam, University of Missouri-Kansas City, Kansas City, MO

P4-8-16

Turning off the catalytic engines of kinases using base editing to identify novel targets for breast cancer therapy

Hanna Karvonen, NYU Grossman School of Medicine, New York, NY

P4-8-18

Functional assessment and targeted therapy strategies development of characteristic CHEK2 missense variants in Chinese breast cancer patients using a microtumor model

Huan Li, Peking University People's Hospital;Beijing Key Laboratory of AI-Enabled Data Governance and Precision Medicine for Breast Cancer, Beijing, China

P4-8-19

Pdia4 is a novel mediator of brain metastasis in inflammatory breast cancer

Xiaoding Hu, MD Anderson cancer center, houston, TX

P4-8-20

Traf3ip2 couples inflammatory signaling to apoptosis resistance and cancer stemness in triple-negative breast cancer

Reza Izadpanah, Tulane University, New Orleans, LA

P4-8-21

Molecular Residual Disease Detected by Circulating Tumor DNA After Neoadjuvant Therapy Predicts Survival Across Early Breast Cancer: A Systematic Review and Meta-analysis

Júnior Samuel de Menezes, Universidade Federal da Bahia, Salvador, Brazil

P4-8-22

High stromal TIL levels are linked to low disseminated tumor cell burden but not the absence of dissemination in breast cancer patients

Laura Weydandt, University hospital Leipzig, Leipzig, Germany

P4-8-23

Variant-specific co-mutation architecture of ESR1 ligand-binding domain mutations in metastatic breast cancer: D538G and Y537S arise in distinct genomic contexts

Mutlu Dogan, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey

P4-8-25

Can Physiological Hormone Cycling Restrain Breast Cancer Progression? Clinical and Experimental Evidence.

Apoorva D Mavatkar, St Johns Research Institute, Bengaluru, India

P4-8-26

New Treatment for BRCA1-mutant cancer through Protein Disulfide Isomerase inhibition

Kimi Kong, UTHSCSA, San Antonio, TX

P4-8-27

Cartilage Microspheres Suppress the Malignant Phenotypes of Breast Cancer Cells

Tenghua Yu, Jiangxi Cancer Hospital & Institute, Nanchang, China

P4-8-28

Tumor-intrinsic iNOS drives obesity-associated immune suppression and promotes therapeutic resistance in triple-negative breast cancer

Ivonne D. Uzair, Houston Methodist Research Institute, Houston, TX

P4-8-29

Spatial transcriptomics and epigenomic profiling of metaplastic breast cancer reveal subtype-specific vulnerabilities and therapeutic implications

Hellen Kuasne, McGill University, Montreal, QC, Canada

P4-8-30

Metabolic adaptation of the sphingolipid rheostat in breast cancer lymph node metastases

Kazuki Moro, Niigata University Graduate School of Medicine, Dentistry and Health Sciences, Niigata City, Japan

P4-9-01

Reticulon 4 Interacting Protein 1 (RTN4IP1) regulates mitochondrial reprogramming and cancer properties in Triple-Negative Breast Cancer.

Alfred Kwabena Dei – Ampeh, Baylor College of Medicine, Houston, TX

P4-9-02

Shmt2 couples one-carbon metabolism to redox homeostasis to drive triple negative breast cancer metastasis

Cheng-Chung Chang, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

P4-9-03

Egr1 promotes an immune-cold, aggressive triple-negative breast cancer

Verena Martinez-Rodriguez, University of Hawaii Cancer Center, Honolulu, HI

P4-9-04

The integrin alpha 6 beta 4 promotes interferon-stimulated gene signatures to amplify inflammatory responses in triple negative breast cancer cells through the IRF1-BRD4 axis

Parvanee Karimpour, University of Kentucky, Lexington, KY

P4-9-05

Regulation of extracellular matrix remodeling by BRCA1

Easwari Kumaraswamy, The University of Kansas Cancer Center, Kansas City, KS

P4-9-07

Clinical and Biological Significance of RFX1 Expression in Breast Cancer: Association With p53 Pathway Activation and Survival Outcomes

Wen-Ying Lin, Taipei Veterans General Hospital, Taipei, Taiwan

P4-9-08

Identification of SPG21 as a new oncogene in triple negative breast cancer

Zhiqiang Qin, University of Arkansas for Medical Sciences, Little Rock, AR

P4-9-10

Characterizing Paraneoplastic Pemphigus autoantigens highly expressed in Basal-like Breast Cancers

Isurika D. Weerasinghe, University of North Carolina at Chapel Hill, Chapel Hill, NC

P4-9-11

Apc11, a ferroptosis suppressor, promotes malignant progression of triple-negative breast cancer by driving ubiquitination-dependent phase separation state transition of downstream factors.

Yingying Xu, The First Hospital of China Medical University, Shenyang, China

P4-9-12

Downregulation of miR-103 is associated with activation of the MELK/FOXM1 axis in TNBC

Seol-Hwa Jeong, Kyungpook National University Chigok Hospital, Daegu, Korea, Republic of

P4-9-13

Single-agent and combination activity of the WEE1 inhibitor azenosertib in preclinical models of Triple-Negative Breast Cancer

Lee Catherine, Zentalis Pharmaceuticals, San Diego, CA

P4-9-14

Comparative molecular profiling of occult (OBC) and overt breast cancer (OvBC)

Elie Rassy, Gustave Roussy Institute, Villejuif, France

P4-9-16

Pet imaging of pharmacologically modulated [⁶⁴cu]cu-atsm retention in hypoxic breast tumors

Thuy Tien Nguyen, Kyungpook National University, Daegu, Korea, Republic of

P4-9-17

Proline-, Glutamic acid-, and Leucine-rich Protein 1 maintains replication fork stability and homologous recombination to prevent replication stress-associated genome instability in triple-negative breast cancer

Khaled Mohamed Nassar, UT health San Antonio, SAN ANTONIO, TX

P4-9-18

Paxalisib uniquely induces durable tumour and immune reprogramming across breast cancer subtypes, challenging the paradigm that dual PI3K/mTOR inhibitors are biologically equivalent

Sudha Rao, QIMR Berghofer Medical Research Institute, Herston, Australia

P4-9-19

The pH regulator GPR89 is tumor-specific dependency and novel drug target associated with oncogene driven ER stress in breast cancer.

Andrew Tutt, The Institute of Cancer Research, London, United Kingdom

P4-9-20

Inhibition of mutant PI3K creates a ferroptosis-sensitive state that can be exploited by GPX4 inhibition

Yuan Wang, UT Southwestern Medical Center, Dallas, TX

P4-9-21

Emotional distress-induced tumor-intrinsic rala-bdnf axis hijacks sensory nerves to drive immune evasion via tumor mhc-i silencing in breast cancer

Sangsang Zhu, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

P4-9-22

Novel Kinase-Independent Mechanism for TNBC Tumor Growth Regulation by Oncogenic PTK6

Criseyda Martinez, Icahn School of Medicine at Mount Sinai, New York, NY

P4-9-23

Enhancing immunotherapy response in breast cancer through SPI1 regulation of PD-L1

Shao-Po Huang, University of Texas Southwestern Medical Center, Dallas, TX

P4-9-25

Higher CTC Burden and Distinct Metastatic Patterns in Invasive Lobular Carcinoma

Maria Teresa T Curiel Garcia, Santiago de Compostela University Hospital, Santiago de Compostela, Spain

P4-9-26

Single-cell atlas reveals a neuroactive myeloid population associated with poor prognosis in human epidermal growth factor receptor 2 (HER2)-positive breast cancer

Luoqi Liang, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

P4-9-27

An integrated multi-omics platform for expanding the actionable target therapeutics landscape in breast cancer

Hee Soo Kim, Geninus, Seoul, Korea, Republic of

P4-9-28

Landscape of focal amplification in Li fraumeni syndrome breast cancer

Nabamita Boruah, Penn Medicine, Philadelphia, PA

P4-9-29

Deciphering the global role of MeCP2 as a transcriptional regulator in breast cancer

Grace C Stroman, University of North Carolina, Chapel Hill, NC

P4-9-30

Alk-10531: a novel cdk2-selective inhibitor that harbors potent activity in multiple disease settings including hr+/her2- models resistant to cdk4/6 inhibitors

Agnieszka K Witkiewicz, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P4-10-01

Building Bridges to Enhance Triple-Negative Breast Cancer Care: A Quality Improvement Exchange Initiative to Advance Multidisciplinary Coordination

Jane Meisel, Emory University, Atlanta, GA

P4-10-02

AI-driven quantitative analysis of HER2 and TROP2 expression dynamics in TNBC patients receiving neoadjuvant chemotherapy ± pembrolizumab: Implications for targeted adjuvant therapy

Ana Christina Garrido-Castro, Dana-Farber Cancer Institute, Boston, MA

P4-10-03

Influence of COVID-19 vaccination or infection on response to neoadjuvant chemoimmunotherapy in early triple-negative breast cancer

Roberto Leon-Ferre, Mayo Clinic, Rochester, MN

P4-10-04

Phase II Trial of Ivonescimab in Combination with Carboplatin and Docetaxel in Patients with Early Stage Triple Negative Breast Cancer (TNBC)[YY1] [YY1]The size limit (including title and body) is 3,400 characters; this does not include spaces

Yuan Yuan, Cedars-Sinai Medical Center, Los Angeles, CA

P4-10-05

Intratumoral Injections of INT230-6 Prior to Neoadjuvant Therapy in Early-Stage Triple Negative Breast Cancer: Efficacy and Safety in the first 14 patients from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Clinical Trial

Markus Joerger, Health Ostschweiz (HOCH), St.Gallen, Switzerland

P4-10-06

Dynamic modulation of soluble MAdCAM-1 during neoadjuvant chemo-immunotherapy (CT+ICI) and response in Triple Negative Breast Cancer

Joana Mourato Ribeiro, Institut Gustave Roussy, Villejuif, France

P4-10-07

Association of Concurrent Beta-Blocker Exposure with Overall Survival in Triple-Negative Breast Cancer Treated with Immune Checkpoint Inhibitors: A Real-World Landmark Analysis

Madison Canning, Emory University, Atlanta, GA

P4-10-08

Regional Lymph Node Immune Transcriptomic Programs Associated with Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer (TNBC)

Nickolas Stabellini, Case Western Reserve University, Cleveland, OH

P4-10-09

Impact of pembrolizumab dosing schedule on clinical outcomes in early triple-negative breast cancer: a multicenter real-world study

Andri Papakonstantinou, Karolinska Institutet, Karolinska Comprehensive Cancer Center, Stockholm, Sweden

P4-10-10

Early peripheral CD8+ T-Cell dynamics associated with immune-related toxicity: pre-planned interim analysis from a prospective cohort of locally advanced TNBC receiving neoadjuvant chemo-immunotherapy

Saya Jacob, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

P4-10-11

Understanding the association between immune-related toxicity and pathological complete response during neoadjuvant immunotherapy for early triple-negative breast cancer: the role of treatment discontinuation – a systematic review and meta-analysis

Claudia Calderaio, IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy

P4-10-12

Pathologic response, recurrence, and immune-related toxicity in BRCA1/2 mutation carriers versus non-carriers with early-stage triple-negative breast cancer treated with neoadjuvant chemoimmunotherapy: a multi-institutional, case-control analysis

Payal D Shah, University of Pennsylvania, Philadelphia, PA

P4-10-13

Incidence, patterns and risk factors of metastatic recurrence after pathologic complete response to neoadjuvant therapy in patients with early-stage triple negative breast cancer

Saya Jacob, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

P4-10-14

Hypoxic neutrophils predict immunotherapy benefit in high-risk, early-stage triple-negative breast cancer

Kent Schechter, University of Chicago, Chicago, IL

P4-10-15

A comprehensive evaluation of soluble PD-L1 and PD-L2 in plasma samples of early triple-negative breast cancer patients participating in the neoMono during treatment with neoadjuvant chemotherapy and atezolizumab

Hans-Christian Kolberg, Knappschaft Kliniken Marienhospital Bottrop, Bottrop, Germany

P4-10-16

Spatial proximity of tumor cells to CD8<sup>+</sup> T cells enhances prediction of pathologic complete response in early-stage triple negative breast cancer with high stromal tumor infiltrating lymphocytes to neoadjuvant chemotherapy

Elizve Barrientos Toro, The University of Texas MD Anderson Cancer Center, Houston, TX

P4-10-17

Spatially informed transcriptomic signatures predict treatment sensitivity and recurrence risk in early triple-negative breast cancer: validation in a large-scale real-world, multicenter cohort

Gabriel Rinnerthaler, Medical University of Graz, Graz, Austria

P4-10-18

Impact of adjuvant pembrolizumab omission on recurrence-free survival in early and locally advanced triple-negative breast cancer: insights from the PETRHA cohort

Alejandro Aranda-Gutierrez, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico

P4-10-19

Association of Muscle and Adiposity with Pathologic Complete Response and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Treated with Neoadjuvant KEYNOTE-522

Jasmine S. Sukumar, University of Texas MD Anderson Cancer Center, Houston, TX

P4-10-20

An anthracycline sparing, pembrolizumab-based, neoadjuvant regimen for stage I triple-negative breast cancer (TNBC): a phase II study

Oluchi Oke, MD Anderson Cancer Center, Houston, TX

P4-10-21

Outcomes of Stage II-III Metaplastic Triple-Negative Breast Cancer Treated with the KEYNOTE-522 Regimen

Madeline Evans, Wayne State University School of Medicine, Detroit, MI

P4-10-22

Platinum-based adjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

Ludovica Antonj, University of Genoa – AOM IRCCS Ospedale Policlinico San Martino, Genova, Italy

P4-10-23

Identification of the RON receptor tyrosine kinase-hypoxia-inducible factor-1 alpha axis as a potential novel therapeutic target for triple negative breast cancer

Garima Sinha, Louisiana State University, New Orleans, LA

P4-10-24

OPERETTA (WJOG14020B): A multicenter phase 2 study of neoadjuvant and adjuvant olaparib plus pembrolizumab following platinum-based chemotherapy plus pembrolizumab in patients with germline BRCA-mutated triple negative breast cancer – efficacy and safety results

Yuko Takahashi, Okayama University Hospital, Okayama, Japan

P4-10-25

The impact of early biological response on pCR rates in patients with early triple negative breast cancer (eTNBC) treated with Atezolizumab in combination with polychemotherapy with or without a pretherapeutic immune therapy window – a translational analysis from the randomized neoadjuvant neoMono trial

Hans-Christian Kolberg, Knappschaft Kliniken Marienhospital Bottrop, Bottrop, Germany

P4-10-26

Suppression of Local and Metastatic Recurrence by Adjuvant PI3K/mTOR Inhibition Through Durable Immune Epigenetic Rewiring Following Neoadjuvant Chemo-Immunotherapy in Stage III Triple-Negative Breast Cancer

Sudha Rao, QIMR Berghofer Medical Research Institute, Herston, Australia

P4-10-27

Body Mass Index (BMI)-Associated Differences in pCR and Circulating Determinants of Response to Immunotherapy in TNBC

Nickolas Stabellini, Case Western Reserve University, Cleveland, OH

P4-10-28

Serial monitoring of circulating tumor DNA to anticipate response in women with triple negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy in the GeparSepto trial

Marion van Mackelenbergh, University Hospital Schleswig-Holstein, Kiel, Germany

P4-10-29

Association between CMV serostatus and pathological complete response in patients with early triple-negative breast cancer (eTNBC) receiving neoadjuvant chemotherapy with or without atezolizumab

Andreas Hartkopf, University Hospital of Tuebingen, Tuebingen, Germany

P4-10-30

Vision: Using real-world data to validate a predictive computational model (Farrsight®-twin) integrating multi-modal data for predicting response to neoadjuvant chemotherapy in triple negative breast cancer (TNBC).

Uzma S Asghar, Guys and St Thomas NHS Foundation, London, United Kingdom

P4-11-01

Benchmarking Real-World Outcomes Against the KEYNOTE-522 Final 7-Year Analysis: A Hispanic-Majority TNBC Cohort Underrepresented in the Original Trial

Daniela Urueta Portillo, UTHSCSA, San Antonio, TX

P4-11-02

Adjuvant carboplatin in early triple-negative breast cancer: a meta-analysis with severity-weighted likelihood of being helped or harmed (LHH).

Armando Orlandi, Fondazione Policlinico Univeristario A. Gemelli IRCCS Rome, Italy, Rome, Italy

P4-11-03

Pathological Response and Survival Outcomes by Chemotherapy Sequence in in Stage II-III Triple Negative Breast Cancer Patients Treated with Neoadjuvant KEYNOTE-522 Regimen

Samuel Srinivasan, Henry Ford Hospital, Detroit, MI

P4-11-04

Incidence and clinical management of diarrhea in patients (pts) with metastatic breast cancer (mBC) treated with sacituzumab govitecan (SG): analysis from a US-based electronic health records database

Vikram Gorantla, University of Pittsburgh Medical Center, Pittsburgh, PA

P4-11-05

Relative Dose Intensity and Pathologic Response among Older Adults receiving Neoadjuvant KEYNOTE-522

Abha Kulkarni, New York Presbyterian/Columbia University Irving Medical Center, New York, NY

P4-11-06

Characteristics and outcomes of triple-negative invasive lobular and apocrine breast carcinomas compared to invasive pleomorphic lobular carcinoma

Ashlyn O'Leary, University of Texas Southwestern Medical Center, DALLAS, TX

P4-11-07

Low Proliferative Triple Negative Breast Cancer Exhibits Distinct Histology, Low Pathologic Complete Response Rates, and Excellent Distant Recurrence-Free Survival

Alexandra Rusz, Stony Brook University Hospital, Stony Brook, NY

P4-11-08

Body Mass Index (BMI)-associated longitudinal circulating proteomic remodeling in TNBC during neoadjuvant chemo-immunotherapy

Jasmin Hundal, Cleveland Clinic, Cleveland, OH

P4-11-09

Age-dependent circulating determinants of response to chemo-immunotherapy in triple-negative breast cancer (TNBC)

Nickolas Stabellini, Case Western Reserve University, Cleveland, OH

P4-11-10

Association between time-of-day neoadjuvant pembrolizumab (pembro) administration and clinical outcomes in early-stage triple-negative breast cancer (TNBC)

Rui Kitadai, Dana-Farber Cancer Institute, Boston, MA

P4-11-11

Pretreatment Emotional Distress and Pathologic Complete Response to Neoadjuvant Chemo-Immunotherapy in Triple-Negative Breast Cancer: A Prespecified Analysis of the NeoSACT Trial

Liulu Zhang, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China

P4-11-12

Response to neoadjuvant chemotherapy in triple negative early breast cancer

ARIADNA GASOL CUDOS, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, LLEIDA, Spain

P4-11-13

Changes in patient reported outcomes associated with immune-related toxicity: interim analysis from a prospective cohort of locally advanced TNBC receiving neoadjuvant chemo-immunotherapy

Saya Jacob, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

P4-11-14

Real-world outcomes of small stage I triple-negative breast cancer according to receipt of systemic therapy

Fernanda Vieira Leão, Instituto Nacional de Câncer, Rio de Janeiro, Brazil

P4-11-15

Neoadjuvant Versus Adjuvant Immunotherapy and Overall Survival in Stage II-III Triple-Negative Breast Cancer: A National Cohort Study

Ismail Ajjawi, Yale School of Medicine, New Haven, CT

P4-11-17

When Biomarkers Fail to Predict: Racial Differences in Response to Neoadjuvant Pembrolizumab for Triple-Negative Breast Cancer

Melanie Sheen, Ochsner, New Orleans, LA

P4-11-18

Jnk1 and jnk2 drive context-dependent immunosuppression in macrophage- and neutrophil-enriched microenvironments in triple-negative breast cancer

Xuemei Xie, University of Hawai'i Cancer Center, Honolulu, HI

P4-11-19

Comprehensive epigenomic plasma profiling to reveal ctDNA dynamics, drug target expression, and biological programs underpinning ADC response in metastatic triple-negative breast cancer

Aparna Gorthi, Precede Biosciences, Cambridge, MA

P4-11-20

Discordant FDG Uptake Between Primary Tumor and Lymph Nodes Is Associated with Pathological Complete Response in Node-Positive Triple-Negative Breast Cancer

Marcin Kubeczko, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

P4-11-21

Real-world treatment patterns and outcomes in patients with early TNBC using the EVOLVE registry

Mariana Chavez-Mac Gregor, The University of Texas MD Anderson Cancer Center, Houston, TX

P4-11-22

Targeting tryptophan catabolism decreases TNBC invasion and metastasis

Jennifer K Richer, University of Colorado Anschutz Medical Campus, Aurora, CO

P4-11-23

Impact of SARS-CoV-2 mRNA Vaccination on Response to Neoadjuvant Pembrolizumab Based KEYNOTE-522 Regimen in Triple-Negative Breast Cancer

Himil Mahadevia, Mayo Clinic Florida, Jacksonville, FL

P4-11-24

Time of Diagnostic Biopsy and Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Exploratory Results from the GAMBIT Real-World Network

Maria Vittoria Dieci, University of Padova, padova, Italy

P4-11-25

Patient-related factors associated with pathologic complete response after neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a nationwide multicenter real-world study

Mario Nalbani, General Hospital Pula, Pula, Croatia

P4-11-26

Pilot clinical decision impact study of TNBCDX for treatment personalization in early triple-negative breast cancer (eTNBC)

Olga Martínez-Sáez, Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain

P4-11-27

Clinicopathologic Predictors of Event-Free Survival (EFS) According to Pathologic Response Following Neoadjuvant Pembrolizumab plus Chemotherapy (CT) for Early Triple-Negative Breast Cancer (TNBC): Real-World Results from the Neo-Real/GBECAM-0123 Study

Romualdo Barroso-Sousa, Brasilia Hospital, Rede Américas, Brasilia, Brazil

P4-11-28

Does PD-L1 Still Matter in Neoadjuvant Chemo-Immunotherapy for Early Triple-Negative Breast Cancer? A Systematic Review and Meta-analysis

Joao Paulo Gonzaga Faria, Oncoclínicas, Belo Horizonte, Brazil

P4-11-29

Postpartum breast cancer and response to immunotherapy in early triple-negative breast cancer

Shiliang Zhang, UCSD, La Jolla, CA

P4-11-30

Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer: Feasibility Analysis from a Non-Randomized, Phase II Multi-Institutional Study

Kamran Ahmed, Moffitt Cancer Center, Tampa, FL

P4-12-01

A phase II exploratory study of iparomlimab and tuvonralimab (QL1706) combined with no, low, or high dose preoperative radiation and chemotherapy in early or locally advanced triple negative breast cancer

Tao Wu, The First People's Hospital of Changde, Changde, China

P4-12-02

Cns relapse after neoadjuvant pembrolizumab in triple-negative breast cancer: incidence, clinicopathological predictors, and the paradox of pathological complete response

Monique C Tavares, AC Camargo Cancer Center, São Paulo, Brazil

P4-12-03

Combined Impact of Obesity and Elevated Baseline Neutrophil-to-Lymphocyte Ratio on Pathologic Complete Response Following Pembrolizumab-Based Neoadjuvant Therapy in Triple-Negative Breast Cancer

Sean Lee, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

P4-12-04

Pembrolizumab-based neoadjuvant therapy in early-stage TNBC: real world biomarker landscape and age-stratified immune toxicity in a multicenter cohort.

Alvaro Romanos Nanclares, Hospital Universitario Virgen de la Victoria, Malaga, Spain

P4-12-05

Pathologic Complete Response and Treatment Tolerability in Older Adults Receiving KEYNOTE-522 for Triple-Negative Breast Cancer

Vanessa Velazquez, University of Texas Health Science Center San Antonio and Mays Cancer Center, San Antonio, TX

P4-12-06

Herthena-breast03: a phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan (HER3-DXd) + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer

Joyce O'Shaughnessy, Texas Oncology, US Oncology and Sarah Cannon Research Institute, Dallas, TX

P4-12-07

Disparities in Germline BRCA1/2 Testing Among Patients with Triple-Negative Breast Cancer

Akram Abushamma, Cleveland Clinic, Akron, OH

P4-12-08

Triple-negative breast cancer in pregnancy-associated settings: oncological outcomes following propensity score-matched comparison against non-pregnant controls — a decade-long single-centre cohort from the middle east

Mahmoud Al-Masri, King Hussein Cancer Center, Amman, Jordan

P4-12-09

Real-world effectiveness of adjuvant capecitabine in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Wesley Antônio Lopes de Lima, Instituto D’Or de Pesquisa e Ensino, São Paulo, Brazil

P4-12-10

Neoadjuvant outcome according to regimen in triple-negative versus low HR+/HER2- early breast cancer

Kyoung Eun Lee, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of

P4-12-11

“Senorita”: systemic and locoregional therapy variations in triple negative breast cancer in older women, an international survey: first results (loco-regional)

Amit Agrawal, Cambridge University Hospitals, Cambridge, United Kingdom

P4-12-12

Potential Clinical Impact of Pembrolizumab Incorporation for Triple-Negative Breast Cancer in Brazil’s Public Health System: A 5-Year Survival Modeling Study

André Mattar, Hospital da Mulher SP, São Paulo, Brazil

P4-12-13

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive biomarkers of pathological complete response and survival in early triple-negative breast cancer treated with neoadjuvant immunotherapy: a real world analysis from the Neo-Real/GBECAM-0123 study

Maíra C Tavares, Instituto D'Or de Pesquisa e Ensino (IDOR), Salvador, Brazil, Salvador, Brazil

P4-12-14

Unfavorable distant outcome despite limited local burden in ipsilateral breast tumor recurrence with an acquired triple-negative phenotype: A benchmark comparison with primary stage I-III triple-negative breast cancer

Ryu Tokui, Osaka Breast Clinic, Osaka, Japan

P4-12-15

Spatial Transcriptomic Profiling Reveals Treatment-Associated Remodeling of Residual Triple-Negative Breast Cancer

Hsu-huan Chou, Chang Gung Memorial Hospital, Linkou, Taoyuan city, Taiwan

P4-12-16

A 27-gene tumor immune classifier captures immune response trajectories following preoperative pembrolizumab and radiation in triple-negative breast cancer.

Tyler J Nielsen, Insight Molecular Diagnostics Inc., Nashville, TN

P4-12-17

Therapeutic Decision-Making and Integration of Tumor-Infiltrating Lymphocytes (TILs) and Circulating Tumor DNA (ctDNA) in Stage I Triple-Negative Breast Cancer: A Multinational Survey of Latin American Medical Oncologists

RONALD S LIMON, oncobolivia, santa cruz, Bolivia, Plurinational State of

P4-12-18

Prognostic Value of Residual Cancer Burden Following Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy in Early Triple-Negative Breast Cancer: A Systematic Review and Meta-analysis

Annanya Ganapathy Subramanian, Government Kilpauk Medical College, Chennai, India

P4-12-19

Residual Prognostic Impact of Baseline Clinical Tumor and Nodal Stage in Triple-Negative Breast Cancer Patients Achieving Pathological Complete Response After Neoadjuvant Chemo-Immunotherapy

Mahmoud Al-Masri, King Hussein Cancer Center, Amman, Jordan

P4-13-02

Comparative Effectiveness of First-Line CDK4/6 Inhibitors Plus Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer: Extended P-VERIFY

Hope S. Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

P4-13-03

Safety in long-term responders with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer treated with inavolisib + palbociclib + fulvestrant in the Phase III INAVO120 trial

Cristina Saura, Vall d’Hebron University Hospital, Barcelona, Spain

P4-13-04

Overall Survival in Prespecified Subgroup Analyses of Atezolizumab Added to Bevacizumab plus Paclitaxel in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (JCOG1919E/AMBITION): A Randomized Phase 3 Trial

Fumikata Hara, Aichi Cancer Center, Nagoya, Japan

P4-13-06

Baseline Metabolic Activity on FDG PET/CT Predicts Progression-Free and Overall Survival in Patients with Metastatic ER-Positive HER2-Negative Breast Cancer Treated with CDK4/6 Inhibitors

Marcin Kubeczko, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

P4-13-07

Comparison of [<sup>18</sup>F]Fluoroestradiol (FES)-PET and [<sup>18</sup>F]Fluorodeoxyglucose (FDG)-PET in patients with newly diagnosed estrogen receptor positive (ER+) metastatic breast cancer: Results from ECOG-ACRIN study EAI142 and implications for choice of imaging for ductal versus lobular cancers

Hannah M Linden, University of Washington/Fred Hutch Cancer Center, Seattle, WA

P4-13-08

Circulating tumor DNA (ctDNA)-based biomarker analysis of datopotamab deruxtecan (Dato-DXd) versus chemotherapy in inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer: a prespecified exploratory analysis of TROPION-Breast01

Barbara Pistilli, Gustave Roussy Cancer Center, Villejuif, France

P4-13-09

Clinical and Genomic Correlates of Primary Resistance to Oral SERDs in patients with HR+/HER2- Advanced Breast Cancer

Giulia Malvezzi, European Institute of Oncology, Milano, Italy

P4-13-10

The prognostic role of the endocrine resistance classification according to the Advanced Breast Cancer (ABC) guidelines: a sub-analysis of the PALLAS trial (AFT-05; ABCSG-42)

Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium

P4-13-11

Updated interim efficacy and safety in the inavolisib + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of multiple treatment combinations in patients with advanced breast cancer

Yeon Hee Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

P4-13-12

Evaluating the landscape and impact of ctDNA ERBB2 mutation in metastatic invasive lobular (ILC) and no special type (NST) breast cancer from a large real-world liquid biopsy cohort

Valerie Gao, UPMC Hillman Cancer Center, Pittsburgh, PA

P4-13-13

Advantage study: does local ablative therapies (LAT) add benefit to first-line CDK4/6 inhibitor plus endocrine therapy (ET) in HR/HER2− oligometastatic breast cancer?

Mariangela Gaudio, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Barcelona, Spain

P4-13-14

Estradiol (E2) suppression with letrozole and impact on outcomes in patients (pts) with advanced hormone receptor-positive (HR+) breast cancer (BC): A post hoc CALGB 40503 (Alliance) correlative study

Megan E Tesch, Dana-Farber Cancer Institute, Boson, MA

P4-13-15

Adebrelimab Plus Fuzuloparib in HRD-Positive, HR+/HER2- Advanced Breast Cancer: Interim Efficacy and Safety Results from an Open-Label, Multicenter Phase II Study

Wenming Cao, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China

P4-13-16

Final overall survival comparison of first-line palbociclib, ribociclib and abemaciclib in patients with Hormone Receptor-positive, Human Epidermal growth factor Receptor2-negative advanced breast cancer (HR+/HER2- aBC): primary results from the multicenter, real-world Italian study PALMARES-2

Claudio Vernieri, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

P4-13-17

Validation of the 21-gene Expression Assay and Clinical-Pathologic Risk Calculator in Young Onset Breast Cancer and Postpartum Breast Cancer

Noy Kaufman Weiss, University of Colorado Anschutz Medical Campus, Aurora, CO

P4-13-18

Real-world time to next treatment or death for patients with HR-positive, HER2-low metastatic breast cancer treated with chemotherapy or trastuzumab deruxtecan

Reshma Mahtani, Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL

P4-13-19

Real-world time to next treatment with targeted therapies in ESR1-mutated ER+/HER2- metastatic breast cancer with PIK3CA, AKT1, or PTEN alterations

Vikram Gorantla, Oncology Hematology Associates at University of Pittsburgh Medical Center, Pittsburgh, PA

P4-13-20

Increasing Yet Underutilized: Real-World ESR1 Testing and Liquid Biopsy UptakeDuring First-line Aromatase Inhibitor (AI) + Cyclin-Dependent Kinase 4/6 inhibitor (CDK4/6i) Therapy in Metastatic Breast Cancer (mBC)

Clara Chen, AstraZeneca, Gaithersburg, MD

P4-13-21

Efficacy of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) for patients with hormone receptor-positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC) with baseline brain metastases: a subgroup analysis of DESTINY-Breast06

Kan Yonemori, National Cancer Center Hospital, Tokyo, Japan

P4-13-22

Clinical outcomes and quality of life by menopausal status among patients receiving palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer in the real- world setting: Results from the PERFORM study

Michael P. Lux, St. Vincenz-Kliniken, Frauenklinik St. Louise Paderborn, Frauenklinik St. Josefs Salzkotten, Paderborn/Salzkotten, Germany

P4-13-23

Real-world effectiveness and safety of Elacestrant in ESR-1 mutated, ER+/HER2-negative advanced breast cancer: a UK multicentre retrospective cohort study

Olubukola Ayodele, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

P4-13-24

Unraveling Early Relapse during adjuvant endocrine therapy and CDK4/6 inhibitors in High-risk HR+/HER2− Early Breast Cancer: The ORCHID Study

Giulio Martinelli, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

P4-13-25

Extended Safety Analysis from the VIKTORIA-1 Randomized Phase 3 Trial of Gedatolisib-based Treatment for HR+/HER2- Advanced Breast Cancer (ABC)

Sara A Hurvitz, Fred Hutchinson Cancer Center, Seattle, WA

P4-13-26

Safety of atirmociclib plus fulvestrant in patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior CDK4/6 inhibitor in the randomized phase 2 FourLight-1 study

Yeon Hee Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

P4-13-27

First disclosure of efficacy and safety results for Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting (LaPemERLA) – a Phase II Study

Yoon Sim Yap, National Cancer Centre Singapore, Singapore, Singapore

P4-13-28

Palazestrant (OP-1250) in combination with everolimus, a phase 1b/2 study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer

Jo Chien, UCSF, San Francisco, CA

P4-13-29

Beyond BOLERO-2: real-world outcomes of Everolomus and Exemestane (EVE+EXE) in patients with HR+/HER2- metastatic breast cancer (mBC) pretreated with CDK4/6 inhibitors.

Daria Filonenko, Moscow Clinical Scientific Center named after A.S.Loginov, Moscow, Russian Federation

P4-14-01

Real‑World effectiveness of first‑line ribociclib + endocrine therapy in HR+/HER2− advanced breast cancer across clinically relevant subgroups: final results from RIBANNA

Achim Wöckel, University Hospital Würzburg, Würzburg, Germany

P4-14-02

A novel therapeutic for CDK4/6 inhibitor resistant ER+ breast cancer

Hanna Irie, Icahn School of Medicine at Mount Sinai, New York, NY

P4-14-03

Emerging ESR1 Mutations After First-Line Aromatase Inhibitor (AI) + Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) in ER+ Metastatic Breast Cancer: Real-World Outcomes and Treatment Patterns

Clara Chen, AstraZeneca, Gaithersburg, MD

P4-14-04

Longitudinal characterization of peripheral blood immune modulation by standard-of-care first line CDK4/6 inhibitor therapy in metastatic breast cancer patients.

Nikhila Kethireddy, City of Hope, Duarte, CA

P4-14-05

Brain metastases in hormone receptor-positive breast cancer: Clinicopathological features, prognostic outcomes, and exploratory molecular profiling—An interim analysis of a retrospective cohort study

Li Xie, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

P4-14-06

Mtor alterations are associated with shorter time on alpelisib in patients with hr-positive/her2-negative metastatic breast cancer

David Arturo Martinez Gamboa, Mayo Clinic, Scottsdale, AZ

P4-14-07

Sacituzumab govitecan plus endocrine therapy after CDK4/6 inhibitor progression in HR-positive/HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH−) metastatic breast cancer: interim results from the phase Ib SoGreat study

Quchang Ouyang, Hunan Cancer Hospital, Changsha, China, Changsha, Hunan, China

P4-14-08

Gedatolisib-based therapy vs other regimens post-CDK4/6i in PIK3CA mutant-type HR+/ HER2- advanced breast cancer (aBC): A systematic literature review (SLR) and network meta-analysis (NMA)

Sara M Tolaney, Dana-Farber Cancer Institute, Boston, MA

P4-14-09

Blood-based HLA-A allele supertype might identify HR+/HER2- metastatic breast cancer patients resistant to CDK4/6 inhibitors

Sabine Kasimir-Bauer, University Hospital Essen, Essen, Germany

P4-14-10

Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) ER degrader, plus palbociclib in ER+/HER2− metastatic, recurrent, or locally advanced unresectable breast cancer: final safety and efficacy results from a phase 1b cohort

Erika P Hamilton, Sarah Cannon Research Institute, Nashville, TN

P4-14-11

Real-world outcomes of metastatic Invasive Lobular Carcinoma (mILC) vs. Invasive Ductal Carcinoma (mIDC) treated with PI3K inhibitors

Natalie Heater, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

P4-14-12

Baseline L3 Skeletal Muscle Index and Treatment Continuity During CDK4/6 Inhibitor Therapy in HR-Positive/HER2-Negative Metastatic Breast Cancer

Nao Torii, Nagoya University Hospital, Nagoya, Japan

P4-14-13

Esr1 testing, positivity rate, and use of the oral serd elacestrant in metastatic breast cancer patients in austria: updated results from the agmt_mbc-registry

Simon P Gampenrieder, Paracelsus Medical University Salzburg, Salzburg, Austria

P4-14-14

Immune targeting of the ESR1 receptor as shared neoantigen for treatment or prevention of estrogen receptor positive breast cancer

Aixa E Soyano, Moffitt Cancer Center, Tampa, FL

P4-14-15

Clinical outcomes with first-line CDK4/6 inhibitors in metastatic invasive lobular versus ductal breast cancer: a real-world institutional analysis.

Grazia Castellano, University of North Carolina at Chapel Hill, Chapel Hill, NC

P4-14-16

Healthcare Access, Survival, and Health-Related Quality of Life in Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer: Final 24-Month Results From the BREAST Study

Vanessa Monteiro Sanvido, Hcor Research Institute, São Paulo, Brazil

P4-14-17

Sequential use of targeted agents with endocrine therapy for hormone-positive metastatic breast cancer: a real-world experience

Kelsey H Natsuhara, University of California San Francisco, San Francisco, CA

P4-14-18

Development of a multi-biomarker predictor of CDK4/6 inhibitor benefit in metastatic breast cancer

George Sledge Jr., Caris Life Sciences, Phoenix, AZ

P4-14-19

Vepdegestrant in patients with ESR1-mutated, ER+/HER2− advanced breast cancer following prior selective estrogen receptor degrader (SERD) therapy: results from a Phase I/II study

Erika P Hamilton, Sarah Cannon Research Institute, Nashville, TN

P4-14-20

Factors Influencing First-Line (1L) cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) Utilization in HR+ HER2- Metastatic Breast Cancer (mBC): Insights from Clinician Documentation

Erica L Mayer, Dana-Farber Cancer Institute, Boston, MA

P4-14-21

Real-world treatment patterns after first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer among patients aged ≥60 years

Pietro De Placido, Università degli Studi di Napoli Federico II, Napoli, Italy

P4-14-22

The novel CDK4-selective inhibitor ALK-13743 has potent single agent and combinatorial activity in HR+/HER2- breast cancer models

Erik S Knudsen, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P4-14-23

Association of 18F-Fluoroestradiol PET Uptake with ESR1 and PIK3CA Alterations in Estrogen Receptor-Positive Metastatic Breast Cancer

Sophia Coraci, Weill Cornell Medicine, New York, NY

P4-14-24

Incidence, Timing and Predictors of Secondary Visceral Metastases in Hormone Receptor-Positive Bone-Only Metastatic Breast Cancer

Alexandre XU-VUILLARD, Gustave Roussy, Villejuif, France

P4-14-25

Targeting Replication Stress Response Defects in ESR1-Mutant Metastatic Breast Cancer

Jessica H Stevens, Baylor College of Medicine, Houston, TX

P4-14-26

Cost-effectiveness of adding ribociclib to endocrine therapy for advanced hormone receptor-positive, HER2-negative breast cancer in a Brazilian public health institution

Laura Testa, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil

P4-14-27

Emergence of ESR1 mutations detected by prospective serial ctDNA analysis during Abemaciclib and aromatase inhibitor in the AMBER trial

Tetsuhiro Yoshinami, Graduate School of Medicine, The University of Osaka, Suita, Japan

P4-14-28

Clinical impact of estrogen receptor gene (ESR1) mutations in HR+/HER2− metastatic breast cancer previously treated with endocrine therapy (ET) and/or CDK4/6 inhibitors

Kevin Kalinsky, Emory University School of Medicine, Atlanta, GA

P4-14-29

Outcomes with iCDK4/6 in 1st line ABC: Heterogeneity between De novo, early and late relapse patients

Marina Vitorino, ULSASI, Amadora, Portugal

P4-14-30

Reversible Therapy Induced Senescence after AURKA Inhibition in ER⁺ Inflammatory Breast Cancer

Tanu Sharma, UT MD Anderson Cancer Center, Houston, TX

P4-15-01

Primary endocrine resistance overrides the favorable prognosis of de novo HR-positive/HER2-negative metastatic breast cancer treated with first-line CDK4/6 inhibitors

Carla M Martín-Abreu, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain

P4-15-02

A Network meta-analysis of PI3K and AKT inhibitors in HR+/HER2- advanced breast cancer with PI3K/AKT pathway alteration

Junaid Anwar, McGovern Medical School, UTHealth Houston, Houston, TX

P4-15-03

Understanding heterogenous bone remodeling in metastatic lobular breast cancer using advanced xenograft models

Matthew J Sikora, University of Colorado Anschutz, Aurora, CO

P4-15-04

From Efficacy to Effectiveness: A Comparative Network Meta-Analysis of Randomized and Real-World Evidence on CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer

Luisana Sisca, Campus Bio-Medico, Roma, Italy

P4-15-05

Death Without First-Line Systemic Therapy in Relapsed/Metastatic HR-Positive/HER2-Negative Breast Cancer: A 10-Year Single-Institution Cohort

Marcela Jurioli Folquito, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil

P4-15-06

Never-in-mitosis A related kinase 9 mediates proliferative and migratory phenotypes in endocrine-resistant, estrogen receptor mutant breast cancer.

Julia Ross Boehling, Tulane University School of Medicine, New Orleans, LA

P4-15-07

Real world efficacy data on second line treatment selection and outcomes after CDK4/6 inhibitor therapy in hormone receptor-positive HER2-negative metastatic breast cancer

Olivia Fahey, The University of Kansas Cancer Center, Westwood, KS

P4-15-08

Evaluating the Clinical Impact of Optimal Genomic Testing Rates and Subsequent Administration of Matched Targeted Treatment in HR+, HER2- Metastatic Breast Cancer: A U.S. Population Model

Reva Basho, Ellison Medical Institute, Los Angeles, CA

P4-15-09

Real-world patient characteristics, treatment sequencing, and outcomes among patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States

Amin Haiderali, Merck & Co., Inc., Rahway, NJ

P4-15-10

Long Duration of CDK4/6 inhibitor benefit does not predict survival after acquired resistance in HR-positive HER2-negative Metastatic Breast Cancer

Mai Tomiguchi, Kumamoto University Hospital, KUMAMOTO, Japan

P4-15-11

Cdk4/6 inhibitor resistance reveals targetable metabolic vulnerabilities in er+ breast cancer

Leanne Price, University of Louisville School of Medicine, Louisville, KY

P4-15-12

Differences in stomatitis among cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer and influence on agent choice: a systematic review and network meta-analysis

Taiga Komatsu, Mount Sinai Morningside/West, New York, NY

P4-15-13

Real-world efficacy and tolerability of elacestrant in ESR1-mutated advanced breast cancer, including outcomes by prior CDK4/6 inhibitor duration and concurrent PI3K-pathway alterations

Chloe Chan, The Royal Marsden Hospital, London, United Kingdom

P4-15-15

Integrated QTc Risk Assessment of Vepdegestrant: Clinical and Concentration-QTc Analyses from VERITAC and VERITAC-2 Trials in ER+/HER2- Advanced or Metastatic Breast Cancer

Lana Tran, Pfizer, Inc, San Diego, CA

P4-15-16

Cns relapse on adjuvant abemaciclib and ribociclib: findings from the england presentation, management and outcomes of patients with bc-cns disease (premo-cns) study

Talvinder Bhogal, Institute of Systems, Molecular and Integrative Biology, Liverpool, United Kingdom

P4-15-17

Real-world analysis and genomic profiles of patients with ER-positive, HER2-negative metastatic breast cancer (mBC) with extended benefit from elacestrant monotherapy: Precision Medicine Action for Cancer (PMAC) experience

Marko Velimirovic, Fred Hutchinson Cancer Center, Seattle, WA

P4-15-18

Overcoming resistance to endocrine therapy and CDK4/6 inhibitors in breast cancer: nonclinical implications for efficacy and safety of the gedatolisib/fulvestrant/palbociclib triplet

Stefano Rossetti, Celcuity Inc., Minneapolis, MN

P4-15-19

Glucocorticoid receptor-mediated modulation of oxidative phosphorylation and mitochondrial function gene expression pathways in lobular breast cancer

Amanda Briceno, UT Southwestern Medical Center, Dallas, TX

P4-15-20

Targeting luminal-to-HER2E transition during endocrine resistance to suppress metastasis in HR+ breast cancer

Baris Cerci, Medical University of South Carolina, Charleston, SC

P4-15-21

Cancer Cells Co-opt Neuronal-like Calcium-Dependent Translational Plasticity to Drive Endocrine Adaptation and Metastasis

Ashish Noronha, UCSF, San Francisco, CA

P4-15-22

Association of concomitant statin use with clinical outcomes in patients receiving CDK4/6 inhibitors for hormone receptor-positive, HER2-negative metastatic breast cancer

Tyler J Kristoff, Emory University School of Medicine, Atlanta, GA

P4-15-23

IGF1R specific targeting of hormone receptor positive breast cancer with immune destruction kills proliferating and quiescent tumors in vivo

Deepali Sachdev, University of Minnesota, Minneapolis, MN

P4-15-24

Preliminary results from the PRISMA study: real-world clinical outcomes of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer in Mexico

Enrique Jose Zamudio Lozoya, CECAN Chihuahua, Chihuahua, Mexico

P4-15-25

A phase 1/2 study of EP0062 (vosilasarm), a first in class oral Selective Androgen Receptor Modulator (SARM), in combination with elacestrant in patients with advanced/metastatic AR+/ER+/HER2-/ESR1m+ breast cancer

Rafael Grochot, Sarah Cannon Research Institute, UK, London, United Kingdom

P4-15-25

Baseline Tumor-Infiltrating Lymphocytes Do Not Predict Response or Survival in HR+/HER2− Metastatic Breast Cancer Treated With First-Line CDK4/6 Inhibitors

Nazan Demir, Koç University Hospital, Istanbul, Turkey

P4-8-04

Duffy null associated neutrophil count and treatment modification during neoadjuvant chemoimmunotherapy for TNBC

Karina P Verma, Boston Medical Center, Boston, MA

P4-4-22

Attenuating Secondary Lymphedema via Matrix-Stimulated Lymphatic Regeneration

Xingyi Du, Peking University People's Hospital, Beijing, China

P4-4-29

Racial Disparity in Clinical Outcomes Across Clinical and Genomic Risk Subgroups in Early Stage Hormone Receptor positive HER2 negative (HR+/HER2−) Invasive Lobular Carcinoma

Yevgeniya Gokun, The Ohio State University, Columbus, OH

P4-4-30

Breast Cancer Screening Disparities in the Upper Midwest: A Mixed Methods Evaluation

Anand K Narayan, University of Wisconsin Carbone Cancer Center, Madison, WI